Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

被引：0
|
作者：
Pemmaraju, Naveen
Carter, Bing Z.
Kantarjian, Hagop M.
Bose, Prithviraj
Kadia, Tapan
Jabbour, Elias J.
DiNardo, Courtney D.
Daver, Naval
Estrov, Zeev
Cortes, Jorge E.
Garcia-Manero, Guillermo
Zhou, Lingsha
Mak, Po Yee
Salinas, Karina
Tuttle, Carla Kay
Pierce, Sherry
Popat, Uday
Verstovsek, Srdan
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
256
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis
    Pemmaraju, Naveen
    Carter, Bing Z.
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Bueso-Ramos, Carlos E.
    DiNardo, Courtney D.
    Bledsoe, Sharon
    Daver, Naval G.
    Popat, Uday
    Konopleva, Marina Y.
    Zhou, Lingsha
    Pierce, Sherry
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Ohanian, Maro
    Qiao, Wei
    Masarova, Lucia
    Wang, Xuemei
    Mak, Po Yee
    Cortes, Jorge
    Jabbour, Elias
    Verstovsek, Srdan
    [J]. BLOOD ADVANCES, 2021, 5 (16) : 3163 - 3173
  • [2] Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
    Pemmaraju, Naveen
    Carter, Bing Z.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Bose, Prithviraj
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Bueso-Ramos, Carlos E.
    DiNardo, Courtney D.
    Bledsoe, Sharon
    Daver, Naval G.
    Popat, Uday
    Konopleva, Marina Y.
    Ohanian, Maro
    Pierce, Sherry A.
    Zhou, Lingsha
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Mak, Po Yee
    Jain, Nitin
    Jabbour, Elias
    Verstovsek, Srdan
    [J]. BLOOD, 2019, 134
  • [3] LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial
    Pemmaraju, Naveen
    Carter, Bing Z.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Bose, Prithviraj
    Daver, Naval G.
    Konopleva, Marina Y.
    Ohanian, Maro N.
    Pierce, Sherry A.
    Zhou, Lingsha
    Estrov, Zeev E.
    Borthakur, Gautam
    Salinas, Karina
    Mak, Po Yee
    Jain, Nitin
    Jabbour, Elias J.
    Verstovsek, Srdan
    [J]. BLOOD, 2018, 132
  • [4] Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)
    Pemmaraju, Naveen
    Carter, Bing Z.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Bose, Prithviraj
    Pierce, Sherry
    Zhou, Lingsha
    Estrov, Zeev
    Tuttle, Carla Kay
    Salinas, Karina
    Mak, Po Yee
    Verstovsek, Srdan
    [J]. BLOOD, 2016, 128 (22)
  • [5] Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells
    Chen, Kuen-Feng
    Lin, Jing-Ping
    Shiau, Chung-Wai
    Tai, Wei-Tien
    Liu, Chun-Yu
    Yu, Hui-Chuan
    Chen, Pei-Jer
    Cheng, Ann-Lii
    [J]. BIOCHEMICAL PHARMACOLOGY, 2012, 84 (03) : 268 - 277
  • [6] A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer
    Infante, Jeffrey R.
    Dees, E. Claire
    Burris, Howard A.
    Zawel, Leigh
    Sager, Jason A.
    Stevenson, Claudina
    Clarke, Kathryn
    Dhuria, Shyeilla
    Porter, Dale
    Sen, Suman K.
    Zannou, Erika
    Sharma, Sushil
    Cohen, Roger B.
    [J]. CANCER RESEARCH, 2010, 70
  • [7] PHASE II STUDY OF LCL161, A SMAC MIMETIC, IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) OR POST-ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS (POST-ET MF
    Pemmaraju, N.
    Kantarjian, H.
    Cortes, J.
    Kadia, T.
    DiNardo, C.
    Estrov, Z.
    Pierce, S.
    Zhou, L.
    Salinas, K.
    Tuttle, C.
    Mak, P. Y.
    Carter, B. Z.
    Verstovsek, S.
    [J]. HAEMATOLOGICA, 2016, 101 : 95 - 95
  • [8] Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial
    Harrison, Claire N.
    Clark, Richard E.
    Chacko, Joseph
    Knapper, Steven
    Yin, John
    Milojkovic, Dragana
    Farquharson, Mira
    Ali, Sabra
    Garg, Mamta K.
    Andrews, Christopher
    Csci, Cstat
    Graham, Susan M.
    Mead, Adam J.
    [J]. BLOOD, 2013, 122 (21)
  • [9] Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial
    Bergsagel, P. Leif
    Lacy, Martha Q.
    Dingli, David
    Kumar, Shaji K.
    Ailawadhi, Sikander
    Dispenzieri, Angela
    Buadi, Francis
    Gertz, Morie A.
    Stewart, A. Keith
    Reeder, Craig B.
    Kosiorek, Heidi E.
    Dueck, Amylou C.
    Lin, Yi
    Chanan-Khan, Asher Alban
    Chesi, Marta
    [J]. BLOOD, 2015, 126 (23)
  • [10] Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
    Pemmaraju, Naveen
    Gupta, Vikas
    Ali, Haris
    Yacoub, Abdulraheem
    Wang, Eunice S.
    Lee, Sangmin
    Schiller, Gary J.
    Sardone, Megan
    Wysowskyj, Halyna
    Chen, Janice
    Brooks, Christopher
    Poradosu, Enrique
    McDonald, Peter
    Rupprecht, Nicole
    Pardanani, Animesh
    Tefferi, Ayalew
    Talpaz, Moshe
    Taparia, Minakshi S.
    Verstovsek, Srdan
    Khoury, Joseph D.
    Patnaik, Mrinal M.
    [J]. BLOOD, 2019, 134
12345